Systematic review and meta-analysis of the prognostic value of the C-reactive protein-albumin-lymphocyte index in patients with lung cancer

doi:10.3969/j.issn.1004-583X.2026.06.002

Abstract

Abstract:

Objective To systematically evaluate the association between the C-reactive protein-albumin-lymphocyte (CALLY) index and prognosis in patients with lung cancer. Methods A computer-based search was conducted in PubMed, Web of Science, the Cochrane Library, Embase, CNKI, VIP, and Wanfang Data, with the search period extending from database inception to April 27, 2026. Study quality was assessed using the Newcastle-Ottawa Scale. Stata 15.0 was used to calculate pooled hazard ratios and 95% confidence intervals. The prognostic value of the CALLY index for overall survival and recurrence-free survival in patients with lung cancer, as reported by multivariable Cox regression analyses, was examined. Results A total of 6 retrospective cohort studies involving 2 459 patients with lung cancer were included. The meta-analysis showed that a high CALLY index was associated with better overall survival (HR=0.59, 95%CI: 0.49-0.69, P<0.01) and recurrence-free survival (HR=0.64, 95%CI: 0.50-0.80, P<0.01) in patients with lung cancer. Conclusion The pretreatment CALLY index is a valuable potential biomarker for predicting overall survival and recurrence-free survival in patients with lung cancer and may support clinical prognostic assessment.

Key words: lung cancer, CALLY index, overall survival, recurrence-free survival

CLC Number:

R734.2

Tang Jia, Xu Yizhou, Wu Jiao, Zhang Jian. Systematic review and meta-analysis of the prognostic value of the C-reactive protein-albumin-lymphocyte index in patients with lung cancer[J]. Clinical Focus, 2026, 41(6): 493-498.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2026.06.002

https://www.lchc.cn/EN/Y2026/V41/I6/493

Figures/Tables 5

References 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834.
[2]	Xu W, Liu X, Yan C, et al. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer[J]. Sci Rep, 2024, 14(1): 7568. doi: 10.1038/s41598-024-57814-4. pmid: 38555313
[3]	Yang Y, Li J, Wang Y, et al. Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis[J]. PLOS One, 2024, 19(11): e0312605. doi: 10.1371/journal.pone.0312605.
[4]	Li ZT, Sun ML, Liu FH, et al. Prognostic nutritional index and cancer prognostic outcomes: An umbrella review of systematic reviews and meta-analyses of observational studies[J]. Adv Nutr, 2026: 100641. doi: 10.1016/j.advnut.2026.100641.
[5]	Iida H, Tani M, Komeda K, et al. Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma[J]. HPB (Oxford), 2022, 24(1): 101-115. doi: 10.1016/j.hpb.2021.06.414.
[6]	Liu XY, Zhang X, Zhang Q, et al. The value of CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in patients with non-small cell lung cancer[J]. Support Care Cancer, 2023, 31(9): 533. doi: 10.1007/s00520-023-07997-9.
[7]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. doi: 10.1007/s10654-010-9491-z. pmid: 20652370
[8]	Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414): 557-560. doi: 10.1136/bmj.327.7414.557.
[9]	Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials[J]. BMJ, 2011, 343: d4002. doi: 10.1136/bmj.d4002.
[10]	Mizota K, Kinoshita F, Giacomo B, et al. The prognostic impact of C-reactive protein-albumin-lymphocyte index (cally index) in patients with surgically resected non-small-cell lung cancer[J]. Ann Surg Oncol, 2025, 33(2): 987-995. doi: 10.1245/s10434-025-18661-3.
[11]	Yoneyama S, Nakamura R, Nakaoka K, et al. Sarcopenia and the C-reactive protein-albumin-lymphocyte index as independent and complementary prognostic factors in resected non-small cell lung cancer[J]. Surg Oncol, 2026, 66: 102421. doi: 10.1016/j.suronc.2026.102421.
[12]	Kim KW, Lee HY, Lee JI, et al. Prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index in surgically treated non-small cell lung cancer[J]. Front Nutr, 2026, 13: 1784875. doi: 10.3389/fnut.2026.1784875.
[13]	Akkar I, Demir H, Babalioglu I, et al. The role of nutritional and inflammatory indices in predicting prognosis in older adults undergoing radiotherapy for lung cancer: NIRT-LC study[J]. J Clin Med, 2026, 15(7): 2756. doi: 10.3390/jcm15072756.
[14]	Konoeda C, Toyokawa G, Shimokawa M, et al. Prognostic impact of the C-reactive protein-albumin-lymphocyte index in patients with resected lung cancer associated with interstitial pneumonia[J]. Surg Today, 2026. doi: 10.1007/s00595-026-03250-y.
[15]	Chen D, Ma Y, Li J, et al. Prognostic and clinicopathological significance of C-reactive protein-albumin-lymphocyte(CALLY) in patients with digestive system neoplasms: A systematic review and meta-analysis[J]. World J Surg Oncol, 2025, 23(1): 114. doi: 10.1186/s12957-025-03779-1. pmid: 40176025
[16]	Zhang L, Wang K, EH, et al. Integrative prognostic value of the CALLY index in cancer patients undergoing surgical resection[J]. Int J Surg, 2026, 112(2): 4047-4058. doi: 10.1097/JS9.0000000000003832.
[17]	Rizo-Téllez SA, Sekheri M, Filep JG. C-reactive protein: A target for therapy to reduce inflammation[J]. Front Immunol, 2023, 14: 1237729. doi: 10.3389/fimmu.2023.1237729.
[18]	Tan Z, Xue H, Sun Y, et al. The role of tumor inflammatory microenvironment in lung cancer[J]. Front Pharmacol, 2021, 12: 688625. doi: 10.3389/fphar.2021.688625.
[19]	Thuya WL, Cao Y, Ho PCL, et al. Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: implications for cancer therapy[J]. Cytokine Growth Factor Rev, 2025, 85: 26-42. doi: 10.1016/j.cytogfr.2025.01.003.
[20]	Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers[J]. Front Oncol, 2022, 12: 1023177. doi: 10.3389/fonc.2022.1023177.
[21]	Zhang J, Quan Y, Wang X, et al. Global epidemiological characteristics of malnutrition in cancer patients: A comprehensive meta-analysis and systematic review[J]. BMC Cancer, 2025, 25(1): 1191. doi: 10.1186/s12885-025-14558-2. pmid: 40684092
[22]	Landgrebe M, Tobberup R, Carus A, et al. GLIM diagnosed malnutrition predicts clinical outcomes and quality of life in patients with non-small cell lung cancer[J]. Clin Nutr, 2023, 42(2): 190-198. doi: 10.1016/j.clnu.2022.12.011.
[23]	Idasiak-Piechocka I, Lewandowski D, 'Swigut W, et al. Effect of hypoalbuminemia on drug pharmacokinetics[J]. Front Pharmacol, 2025, 16: 1546465. doi: 10.3389/fphar.2025.1546465.
[24]	Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, et al. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: A multidimensional approach[J]. Nat Rev Clin Oncol, 2025, 22(3): 163-181. doi: 10.1038/s41571-024-00984-x. pmid: 39820025
[25]	Wu J, Duan Z, Qian J, et al. Predictive value of the systemic immune-inflammation index and geriatric nutritional risk index on the efficacy of immunotherapy and survival prognosis in advanced non-small cell lung cancer: A retrospective study[J]. Am J Cancer Res, 2026, 16(3): 921-936. doi: 10.62347/QMNU5628.
[26]	Şeber ES, Elçiçek ÖF, Çavdar E, et al. Inflammation-based prognostication in extensive-stage small cell lung cancer in the first-line setting: The advanced lung inflammation index and the others[J]. Asia Pac J Clin Oncol, 2025, 21(6): 654-659. doi: 10.1111/ajco.14200.

作者	发表年份	国家	研究时间 (年)	样本量	年龄 (岁)	样本获取时间	治疗	研究类型	截断值获取方法	截断值	结局指标	NOS评分 (分)
Liu等^[6]	2023	中国	2013-2018	557	61(54~67)	治疗前(首次入院后24小时内)	手术、放疗、化疗	a	最大选择秩统计量	1.32	OS	7
Mizota等^[10]	2025	日本	2013-2018	634	69(63~76)	治疗前	手术	a	受试者工作特征曲线	6.20	OS; RFS	6
Yoneyama等^[11]	2026	日本	2016-2023	329	72(67~76)	治疗前(手术前7天内)	手术	b	受试者工作特征曲线	6.53	OS; RFS	7
Kim等^[12]	2026	韩国	2011-2020	680	66(59~73)	治疗前(术前1个月内)	手术	b	最大选择秩统计量	5.14	OS; RFS	7
Akkar等^[13]	2026	土耳其	2020-2024	174	69(65~87)	治疗前(放疗前14天内)	放疗	b	受试者工作特征曲线	0.50	OS	7
Konoeda等^[14]	2026	日本	2011-2021	85	73(66~78)	治疗前(手术前1个月内)	手术	b	受试者工作特征曲线	0.97	OS; RFS	6

作者	发表年份	国家	研究时间 (年)	样本量	年龄 (岁)	样本获取时间	治疗	研究类型	截断值获取方法	截断值	结局指标	NOS评分 (分)
Liu等^[6]	2023	中国	2013-2018	557	61(54~67)	治疗前(首次入院后24小时内)	手术、放疗、化疗	a	最大选择秩统计量	1.32	OS	7
Mizota等^[10]	2025	日本	2013-2018	634	69(63~76)	治疗前	手术	a	受试者工作特征曲线	6.20	OS; RFS	6
Yoneyama等^[11]	2026	日本	2016-2023	329	72(67~76)	治疗前(手术前7天内)	手术	b	受试者工作特征曲线	6.53	OS; RFS	7
Kim等^[12]	2026	韩国	2011-2020	680	66(59~73)	治疗前(术前1个月内)	手术	b	最大选择秩统计量	5.14	OS; RFS	7
Akkar等^[13]	2026	土耳其	2020-2024	174	69(65~87)	治疗前(放疗前14天内)	放疗	b	受试者工作特征曲线	0.50	OS	7
Konoeda等^[14]	2026	日本	2011-2021	85	73(66~78)	治疗前(手术前1个月内)	手术	b	受试者工作特征曲线	0.97	OS; RFS	6

亚组	研究数量	样本量	HR	95%CI	I²(%)
国家
中国	1	557	0.71	0.55~0.91	-
韩国	1	680	0.40	0.26~0.64	-
日本	3	1048	0.54	0.40~0.71	10.1
研究类型
多中心	2	1191	0.68	0.56~0.84	0
单中心	3	1094	0.43	0.32~0.57	0
截断值获取方法
最大选择秩统计量	2	1237	0.62	0.50~0.77	78.9
受试者工作特征曲线	3	1048	0.54	0.41~0.71	10.1

亚组	研究数量	样本量	HR	95%CI	I²(%)
国家
中国	1	557	0.71	0.55~0.91	-
韩国	1	680	0.40	0.26~0.64	-
日本	3	1048	0.54	0.40~0.71	10.1
研究类型
多中心	2	1191	0.68	0.56~0.84	0
单中心	3	1094	0.43	0.32~0.57	0
截断值获取方法
最大选择秩统计量	2	1237	0.62	0.50~0.77	78.9
受试者工作特征曲线	3	1048	0.54	0.41~0.71	10.1